This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ESMO, Munich, Germany, 19-23 October 2018

Effectiveness of afatinib in the clinical practice - first results of the GIDEON trial: ​a prospective non-interventional study in EGFR-mutated NSCLC in Germany

Wolfgang M. Brueckl, Eckart Laack, Martin Reck, Frank Griesinger, Helmut Schäfer, Cornelius Kortsik, Tobias Gaska, Justyna Rawluk, Stefan Krüger, Konrad Kokowski, Stephan Budweiser, Andrea Schueler, Stephan Kiessling

1200.205 GIDEON ESMO 2018

FOR HEALTHCARE PROFESSIONALS ONLY.

In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.

Disclaimer